Medical
La Trobe climbs in ARWU global ranking
La Trobe University is continuing to climb in one of the world’s best recognised rankings – the Academic Ranking of World Universities (ARWU).
The University has placed 307 in the 2019 ARWU results released by ShanghaiRanking today, up 10 places from last year and an increase of more than 193 positions in the last five years.
La Trobe is placed 17th nationally in the ranking and fourth in Victoria.
The University continues to be rated in the top 400 of all three major world university rankings: the ARWU, QS and Times Higher Education World University Rankings, making it among the world’s top 1.2 per cent of universities.
In addition, all University research that was assessed in the 2018 Excellence in Research for Australia evaluation was rated in the top three categories of: at world standard, above world standard or well above world standard.
Deputy Vice-Chancellor (Research and Industry Engagement) Professor Susan Dodds welcomed La Trobe’s improved position in the ARWU ranking, saying it again confirmed the University’s position as a world-leading University for research.
“La Trobe’s global rankings growth is testament to our exceptional academic staff who are conducting high-impact research addressing some of the biggest challenges of our times, and who are working in close collaboration with industries and research partners across the world,” Professor Dodds said.
The ARWU ranks universities with several indicators of academic or research performance, including alumni and staff winning Nobel Prizes and Fields Medals, highly cited researchers, papers published in Nature and Science, papers indexed in major citation indices, and the per capita academic performance of an institution.
More information on University rankings can be found at the University’s website.
You may also like Therapeutics and the importance of cancer research in Australia
Medical
NSW Health to settle ‘largest’ class action
A class action alleging NSW Health underpaid clinicians has settled after the department agreed to a payout of nearly a […]
MoreNews & Trends - Pharmaceuticals
Lilly’s first-in-class therapy PBS listed for early breast cancer after 15-year gap
Pharma News: Australians diagnosed with early-stage breast cancer, particularly those at high risk of recurrence, will gain access to the […]
MoreNews & Trends - Pharmaceuticals
AstraZeneza secures four PBAC nods in oncology, diabetes, kidney and rare diseases
Pharma News: AstraZeneca has scored four positive Pharmaceutical Benefits Advisory Committee (PBAC) recommendations following the March meeting. These recommendations, spanning […]
MoreNews & Trends - Pharmaceuticals
PBAC recommendation to reshape prescribing in heart failure
Pharma News: Aligned with the government’s Scope of Practice Review, the Pharmaceutical Benefits Advisory Committee (PBAC) has made a practice-changing […]
More